| Autor: |
Castillero F; Oncology Department, Instituto Oncológico Nacional de Panamá, 04433, Panamá., Castillo-Fernández O; Oncology Department, Instituto Oncológico Nacional de Panamá, 04433, Panamá., Jiménez-Jiménez G; Oncology Department, Hospital Dr. Rafael Ángel Calderón Guardia, San José 10101, Costa Rica., Fallas-Ramírez J; Instituto de Investigaciones Farmacéuticas, Facultad de Farmacia, Universidad de Costa Rica, San José 11501, Costa Rica., Peralta-Álvarez MP; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), México City 14080, México.; Laboratory of Personalized Medicine, Instituto Nacional de Cancerología (INCan), México City 14080, México., Arrieta O; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), México City 14080, México.; Laboratory of Personalized Medicine, Instituto Nacional de Cancerología (INCan), México City 14080, México. |
| Abstrakt: |
The advances in cancer therapy have included the development of drugs that inhibit immune checkpoint ligands. Two types of immune checkpoint inhibitors, both antibodies that target CTLA-4 and PD-1, have been approved for its use in NSCLC and melanoma as first-line or second-line therapy. Sadly, not desirable consequences of immunotherapy are immune-related adverse events. immune-related hypophysitis is the most common endocrine adverse event after thyroid disfunction. The particularity of endocrine immune-related adverse events is their non-reversibility, with incidence and prevalence destined to increase in the coming years, particularly if this form of therapy is used in the future for earlier stages of cancer. Therefore, hypophysitis represents a challenge for the physician, sometimes occurring without specific symptomatology and which should be considered for clinical management. In this review, we describe the current data regarding the pathophysiology and management for immune-related hypophysitis. |
